Is Biofrontera Inc. (BFRI) a Buy, Sell, or Hold?
Biofrontera Inc.
NASDAQ:BFRI
$1.06 USD
-$0.05 (-4.5%)
- Volume
- 452.06K
- Average Volume
- 261.06K
- Market Capitalization
- $13.57M
- P/E Ratio
- -0.95
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $1.21
- Year Low
- $0.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.20
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Hermann Lübbert |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Current Symbol | BFRI |
| CUSIP | 09077D209 |
| CIK | 0001858685 |
| Web | https://www.biofrontera-us.com |
| Phone | 781 245 1325 |
| Currency | USD |
| Employees | 92 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.27 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.20 |
| Quick Ratio | 1.09 |
| Cash Ratio | 0.58 |
Sales & Book Value
| Annual Sales | $41.7M |
| Price / Sales | 0.31 |
| Cash Flow | -0.80 |
| Price / Cash Flow | -1.46 |
| Price / Book | 2.04 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.9 |
| Trailing P/E Ratio | -0.95 |
| PEG Ratio | -0.03 |
| P/E Growth | -0.03 |
| Net Income | $-10.54M |
| Net Margin | -25.66% |
| Pretax Margin | -25.60% |
| Return on Equity | -476.72% |
| Return on Assets | -44.72% |
Financials Score
| AltmanZ Score | -6.63 |
| Piotroski Score | 2.00 |
| Working Capital | 2.24M |
| Total Assets | 24.79M |
| Ebit | -10.84M |
| Market Cap | 14.21M |
| Total Liabilities | 18.72M |
Poll Results
About Biofrontera Inc. (NASDAQ:BFRI) Stock
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. ...
Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-11 11:42:13
Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
2026-05-21 09:15:00
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
2026-05-21 09:15:00
WOBURN, Mass. , May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates
2026-05-14 10:25:23
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.47 per share a year ago.
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
2026-05-14 07:30:00
Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three months ended March 31, 2026 and provided a business update.
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
2026-05-13 09:00:00
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo, and help raise awareness of AK and the importance of comprehensive sun protection Actinic Keratosis affects an estimated 58 million Americans and, if left untreated, can develop into squamous cell carcinoma1 Woburn, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the return of the Hats On Campaign for its second consecutive year.
2026-05-08 16:00:00
WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Thursday, May 14, 2026. The Company will host a conference call on Thursday, May 14, 2026 at 11:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information
2026-05-08 16:00:00
WOBURN, Mass. , May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months ended March 31, 2026 after the close of the U.
Frequently Asked Questions
-
What is the current Biofrontera Inc. (BFRI) stock price?
-
Biofrontera Inc.(NASDAQ:BFRI) stock price is $1.06 in the last trading session. During the trading session, BFRI stock reached the peak price of $1.205 while $0.555 was the lowest point it dropped to. The percentage change in BFRI stock occurred in the recent session was --4.5% while the dollar amount for the price change in BFRI stock was -$-0.05.
-
BFRI's industry and sector of operation?
-
The NASDAQ listed BFRI is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of BFRI?
-
Hermann Luebbert | Chief Executive Officer, President & Chairman
Daniel Hakansson | Senior Corporate Counsel
Eugene Frederick Leffler | Chief Financial Officer
Jon Lyons | Vice President of Scientific & Medical Affairs
Erica F. Gates | VP of Finance & Principal Accounting Officer -
How many employees does BFRI have?
-
Number of BFRI employees currently stands at 92. BFRI operates from 660 Main Street, Woburn, MA 01801, US.
-
Link for BFRI official website?
-
Official Website of BFRI is: https://www.biofrontera-us.com
-
How do I contact BFRI?
-
BFRI could be contacted at phone #781 245 1325 and can also be accessed through its website. BFRI operates from 660 Main Street, Woburn, MA 01801, US.
-
How many shares of BFRI are traded daily?
-
The average number of BFRI shares traded daily for last 3 months was 261.06K.
-
What is the market cap of BFRI currently?
-
The market value of BFRI currently stands at $13.57M with its latest stock price at $1.06